Independent health providers: accessing lateral flow tests, DSHC (updated 3rd June 2021)
Independent health providers can access lateral flow testing kits directly from NHS Test and Trace replacing the ordering route provided by NHS England and NHS Improvement. 3 June 2021Updates to the lateral flow testing terms and conditions for independent health providers to show the Provider will communicate any changes in their eligibility status to the Test Subject. 25 May 2021Updated ' Lateral flow testing terms and conditions for independent health providers ' to reflect that DHSC will support the provider to carry out and facilitate COVID-19 testing of the provider ' s staff who come into contact with NHS patien...
Source: Current Awareness Service for Health (CASH) - June 3, 2021 Category: Consumer Health News Source Type: news

New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more diffic...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors, follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. Today’s BTD marks the 11th received by Janssen’s Oncology The...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlighting ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Data on First-in-Class Talquetamab at ASCO Suggesting Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
May 24, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today follow-up data from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of the investigational product talquetamab, the only off-the-shelf T-cell redirecting bispecific antibody in clinical development to target both GPRC5D, a novel multiple myeloma target, and CD3 on T-cells (NCT03399799).[1],[2],[3] With a median follow-up of more than six months, updated results in 30 patients with relapsed or refractory multiple myeloma treated with talquetamab by subcutaneous (SC) administration at the recommended P...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen ’s Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
We reported initial findings for teclistamab at ASCO 2020, and study updates have observed a deepening of responses that have shown to be durable in a significant percentage of patients with relapsed or refractory multiple myeloma,” said Amrita Y. Krishnan, M.D., Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research and Chief, Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, and study investigator. “Teclistamab exposure was sustained across the dosing interval and exceeded target levels, and consistent T-cell activation was observed. ...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that ...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Higher education providers: coronavirus (COVID-19), DforE (updated 20th May 2021)
Coronavirus (COVID-19) operational guidance for higher education providers. 20 May 2021 Guidance converted to HTML to make it easier to read. There are no changes to any of the guidance from the update on 10 May. 10 May 2021 We have withdrawn ' Students returning to, and starting, higher education during spring and summer 2021 ' and updated ' Higher education coronavirus (COVID-19) operational guidance ' with information on Step 3 of the Roadmap, outbreak plans, face coverings, testing asymptomatic students and staff using lateral flow device tests (LFDs), new and returning students travelling from overse...
Source: Current Awareness Service for Health (CASH) - May 20, 2021 Category: Consumer Health News Source Type: news

Guidance for parents and carers of children attending out-of-school settings during the coronavirus (COVID-19) outbreak, DforE (updated 20th May 2021)
Guidance for parents and carers of children attending community activities, holiday or after-school clubs, tuition and other out-of-school settings. 20 May 2021 We have converted the guidance to HTML to make it easier to read. We have not changed any of the guidance from the update on 10 May. 10 May 2021 Updated to provide additional guidance on residential visits, which can c ommence from Step 3. Updated the guidance on use of face coverings, indoor group sizes and parental attendance at out-of-school settings.
Source: Current Awareness Service for Health (CASH) - May 20, 2021 Category: Consumer Health News Source Type: news

Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated data from the Phase 1 CHRYSALIS study showing treatment with amivantamab in combination with lazertinib led to a median duration of response (DOR) of 9.6 months in chemotherapy-naïve patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib.[1] These data, which will be presented in an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting ...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19: how to work safely in domiciliary care in England, PHE (updated 18th May 2021)
This is a resource for those working in domiciliary care providing information on the use of personal protective equipment (PPE). Update in this version (published 18th May 2021) - added note explaining that the infographics are being reviewed and will be updated shortly in line with the guidance. Update in version published 6 April 2021 - introduced recommendations to change PPE after each episode of personal care, and new recommendations around use of eye protection when delivering personal care within 2 metres. Guidance provided in HTML format only.
Source: Current Awareness Service for Health (CASH) - May 19, 2021 Category: Consumer Health News Source Type: news

Coronavirus (COVID-19) testing for homecare workers, DHSC (updated 14th May 2021)
Sets out how homecare (domiciliary care) workers in England can collect, complete and register test kits for coronavirus (COVID-19). 14 May 2021Added 8 translations of ' Testing for homecare workers (summary poster for print) ' . Removed ' A testing service for homecare workers in England ' (HTML and PDF versions), as these have been added to a new page: ' Coronavirus (COVID-19) testing for homecare workers: information for agencies ' . 22 April 2021Updated ' A testing service for homecare workers in England (PDF version) ' , page 5, to reflect that personal assistants in England can access regular testing.
Source: Current Awareness Service for Health (CASH) - May 14, 2021 Category: Consumer Health News Source Type: news

Join Us & Bring Your Thread of Knowledge to Help Us Stitch Our Region 4 Fabric
Come meet your Network of the National Library of Medicine Region 4 staff for the states of Arizona, New Mexico, Colorado, Utah, Wyoming, Idaho, Montana, North Dakota and South Dakota. We will listen to your ideas and answer your questions. The meeting is free for anyone to attend.   NNLM Day at MLA Region 4 Preview Monday, May 17 1:30 – 2:30 pm MDT 12:30 – 1:30 pm AZ Time   Meeting Link: https://nih.zoomgov.com/j/1614228020?pwd=NTVhdFQ5RW9ycXQxUkEwVEVsWjVXQT09 Meeting ID: 161 422 8020 Passcode: 396922   For more information on regional and national sessions of NNLM Day at MLA, visit https://www.nlm.nih.gov...
Source: MCR News - May 12, 2021 Category: Databases & Libraries Authors: liaison Tags: #CC/Academic List #Health Interest List #Health Sciences List #Public/K-12 List Source Type: news

Join us and bring your thread of knowledge to help us stitch our Region 4 fabric.
Let’s talk! Come meet your Network of the National Library of Medicine staff for the states of Arizona, New Mexico, Colorado, Utah, Wyoming, Idaho, Montana, North Dakota, and South Dakota (Region 4). We want to meet you, hear your ideas, and answer your questions. The meeting is free for anyone to attend.   NNLM Day at MLA Region 4 Preview Monday, May 17 1:30 – 2:30 pm MDT 12:30 – 1:30 pm AZ Time   Meeting Link: https://nih.zoomgov.com/j/1614228020?pwd=NTVhdFQ5RW9ycXQxUkEwVEVsWjVXQT09 Meeting ID: 161 422 8020 Passcode: 396922   For more information on regional and national sessions of NNLM Day at MLA, vis...
Source: MCR News - May 12, 2021 Category: Databases & Libraries Authors: liaison Tags: #CC/Academic List #Health Interest List #Health Sciences List #Public/K-12 List Source Type: news

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20